Clinical Efficacy of Bifidobacterium and Lactobacillus Triple Viable Bacteria Tablets Combined with Flu-pentixol and Melitracen in Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
Objective To investigate the clinical efficacy and adverse reactions of bifidobacterium and lac-tobacillus triple viable bacteria tablets combined with flupentixol and melitracen in the treatment of diar-rhea-predominant irritable bowel syndrome.Methods A total of 60 patients with diarrhea-predominant irritable bowel syndrome admitted to our hospital from January 2021 to June 2023 were randomly divided into observation group and control group,with 30 cases in each group.The control group was given bifidobacterium and lactobacillus triple viable bacteria tablets orally,and the observation group received flupentixol and melitracen orally on the basis of the control group.Gastrointestinal symptom score,im-mune function index and adverse reactions were compared between the two groups.Results After treat-ment,symptom severity index and symptom frequency index in the observation group were lower than those in the control group(P＜0.05).The levels of immune factors CD4 and CD8 in the observation group were higher than those in the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(16.67％VS 10.00％,P＞0.05).Conclusion Bifidobacterium and lactobacillus triple viable bacteria tablets combined with flupentixol and melitracen in the treatment of diarrhea-predominant irritable bowel syndrome can improve the clinical symptoms and im-munity of patients,which is safe and worthy of clinical application.
Diarrhea-predominant irritable bowel syndromeBifidobacterium and lactobacillus triple vi-able bacteria tabletsFlupentixol and melitracenEfficacy
NETL
NSTL
万方数据
